Evidence map›Paper›PMID 34187527›Full record

SynthesisTrials2021

Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)-estimation of adverse event risks.

Regina Stegherr, Claudia Schmoor, Jan Beyersmann, Kaspar Rufibach, Valentine Jehl, Andreas Brückner, Lewin Eisele, Thomas Künzel, Katrin Kupas, Frank Langer and 5 more

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in Trials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Electrocardiographic risk stratification in patients with a primary prophylactic implantable cardioverter defibrillator: can future arrhythmias correlating with sudden cardiac death be predicted?Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 2 countries.

Regina StegherrInstitute of Statistics, Ulm University, Ulm, Germany.
Claudia SchmoorClinical Trials Unit, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg im Breisgau, Germany.
Jan BeyersmannInstitute of Statistics, Ulm University, Ulm, Germany.
Kaspar RufibachF. Hoffmann-La Roche, Basel, Switzerland.
Valentine JehlNovartis Pharma AG, Basel, Switzerland.
Andreas BrücknerNovartis Pharma AG, Basel, Switzerland.
Lewin EiseleJanssen-Cilag GmbH, Neuss, Germany.
Thomas KünzelF. Hoffmann-La Roche, Basel, Switzerland.
Katrin KupasBristol-Myers-Squibb GmbH & Co. KGaA, München, Germany.
Frank LangerLilly Deutschland GmbH, Bad Homburg, Germany.
Friedhelm LeverkusPfizer, Berlin, Germany.
Anja LoosMerck KGaA, Darmstadt, Germany.
Christiane NorenbergBayer AG, Wuppertal, Germany.
Florian VossBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
Tim FriedeDepartment of Medical Statistics, University Medical Center Göttingen, Humboldtallee 32, Göttingen, 37073, Germany. tim.friede@med.uni-goettingen.de.ORCID http://orcid.org/0000-0001-5347-7441
Novartis (Switzerland) · CHRoche (Switzerland) · CHBayer (Germany) · DEBoehringer Ingelheim (Germany) · DEBristol-Myers Squibb (Germany) · DEEli Lilly (Germany) · DEJanssen (Germany) · DEMerck (Germany) · DEPfizer (Germany) · DEUniversitätsmedizin Göttingen · DEUniversity of Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe SAVVY project aims to improve the analyses of adverse events (AEs), whether prespecified or emerging, in clinical trials through the use of survival techniques appropriately dealing with varying follow-up times and competing events (CEs). Although statistical methodologies have advanced, in AE analyses, often the incidence proportion, the incidence density, or a non-parametric Kaplan-Meier estimator are used, which ignore either censoring or CEs. In an empirical study including randomized clinical trials from several sponsor organizations, these potential sources of bias are investigated. The main purpose is to compare the estimators that are typically used to quantify AE risk within trial arms to the non-parametric Aalen-Johansen estimator as the gold-standard for estimating cumulative AE probabilities. A follow-up paper will consider consequences when comparing safety between treatment groups.

methodsEstimators are compared with descriptive statistics, graphical displays, and a more formal assessment using a random effects meta-analysis. The influence of different factors on the size of deviations from the gold-standard is investigated in a meta-regression. Comparisons are conducted at the maximum follow-up time and at earlier evaluation times. CEs definition does not only include death before AE but also end of follow-up for AEs due to events related to the disease course or safety of the treatment.

resultsTen sponsor organizations provided 17 clinical trials including 186 types of investigated AEs. The one minus Kaplan-Meier estimator was on average about 1.2-fold larger than the Aalen-Johansen estimator and the probability transform of the incidence density ignoring CEs was even 2-fold larger. The average bias using the incidence proportion was less than 5%. Assuming constant hazards using incidence densities was hardly an issue provided that CEs were accounted for. The meta-regression showed that the bias depended mainly on the amount of censoring and on the amount of CEs.

conclusionsThe choice of the estimator of the cumulative AE probability and the definition of CEs are crucial. We recommend using the Aalen-Johansen estimator with an appropriate definition of CEs whenever the risk for AEs is to be quantified and to change the guidelines accordingly.

Indexed as

Follow-Up StudiesHumansIncidenceProbabilitySurvival AnalysisAalen-Johansen estimatorAdverse eventsCompeting eventsDrug safetyIncidence densityIncidence proportionKaplan-Meier estimator

Identifiers

PMID34187527
PMCPMC8244188
OpenAlexW3079308787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.